Although this is the first study to report on Tetranectin as a potential heart failure biomarker, these observations were made on a relatively small cohort, and validation studies in additional representative screening populations harbouring multiple different diagnoses, such as cardiomyopathy and acute decompensated HF (ADHF), would help confirm the cardiac specificity of Tetranectin as a prospective biomarker. This evidence concerns the gene CLEC3B and heart failure.